pravastatin has been researched along with Recrudescence in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (34.85) | 18.2507 |
| 2000's | 24 (36.36) | 29.6817 |
| 2010's | 18 (27.27) | 24.3611 |
| 2020's | 1 (1.52) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, S; Hosomi, N; Kagimura, T; Kitagawa, K; Maruyama, H; Matsumoto, M; Minematsu, K; Nagai, Y; Nakagawa, Y; Nezu, T; Origasa, H; Uchiyama, S | 2 |
| Gembruch, U; Kühr, M; Merz, WM; Otten, LA; van der Ven, K | 1 |
| Advani, AS; Appelbaum, FR; Erba, HP; Li, H; Liedtke, M; List, AF; Medeiros, BC; Michaelis, LC; O'Dwyer, K; Othus, M | 1 |
| Hosomi, N; Kagimura, T; Kitagawa, K; Maruyama, H; Matsumoto, M; Minematsu, K; Nagai, Y; Nakamura, M; Ohtsuki, T; Origasa, H; Uchiyama, S | 1 |
| Aoki, S; Hosomi, N; Kagimura, T; Kitagawa, K; Koga, M; Maruyama, H; Matsumoto, M; Minematsu, K; Nagai, Y; Nezu, T; Ohtsuki, T; Origasa, H; Suzuki, R; Toyoda, K; Uchiyama, S; Wada, S; Yasaka, M | 1 |
| Blankenberg, S; Colquhoun, D; Funke-Kaiser, A; Hunt, D; Mann, K; Simes, J; Sullivan, D; Sydow, K; Tonkin, AM; West, M; White, H; Zeller, T | 1 |
| Advani, AS; Appelbaum, FR; Copelan, E; List, AF; McDonough, S; Mulford, DA; Othus, M; Sekeres, MA; Willman, C | 1 |
| Ebisawa, S; Ikeda, U; Izawa, A; Kagoshima, M; Kashima, Y; Kitabayashi, H; Koyama, J; Miura, T; Miyashita, Y; Sakurai, S; Tomita, T; Yamamoto, H | 1 |
| Cannon, CP; Khera, AV; Murphy, SA; Qamar, A; Rader, DJ; Sabatine, MS | 1 |
| Aoki, S; Fukushima, M; Hosomi, N; Ibayashi, S; Kitagawa, K; Kohriyama, T; Maruyama, H; Matsumoto, M; Minematsu, K; Mori, E; Nagai, Y; Nakamura, M; Nezu, T; Ohtsuki, T; Origasa, H; Shinohara, Y; Sunami, N; Takagi, M; Terayama, Y; Uchiyama, S; Yamaguchi, T; Yokota, C | 1 |
| de Craen, AJ; de Ruijter, W; Drewes, YM; Ford, I; Gussekloo, J; Jukema, JW; Mertens, BJ; Mooijaart, SP; Poortvliet, RK; Sattar, N; Stott, DJ; van Peet, PG; Wijsman, LW | 1 |
| Hosomi, N; Kitagawa, K; Koga, M; Matsumoto, M; Minematsu, K; Nagai, Y; Origasa, H; Toyoda, K; Uchiyama, S; Yasaka, M | 1 |
| Hosomi, N; Kagimura, T; Kitagawa, K; Matsumoto, M; Minematsu, K; Nagai, Y; Nakamura, M; Ohtsuki, T; Origasa, H; Uchiyama, S | 1 |
| Elsais, A; Kerty, E; Lund, C | 1 |
| Barnes, EH; Colquhoun, D; Keech, A; Nestel, P; Pollicino, C; Simes, J; Söderberg, S; Tonkin, AM; Yallop, J | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Morrow, DA; Ray, KK; Ridker, PM | 1 |
| Becker, DJ; Farrar, JT; French, B; Gordon, RY; Halbert, SC; Morris, PB; Rader, DJ; Schmitz, K; Thompson, PD | 1 |
| Cui, J; Forbes, A; Hunt, D; Kirby, A; Marschner, I; Simes, J; Tonkin, A; West, M | 1 |
| Cannon, CP; Khera, AV; Qin, J; Rader, DJ; Wolfe, ML | 1 |
| Braunwald, E; Pfeffer, MA; Ridker, PM; Sacks, FM | 1 |
| Cannon, CP; De Lemos, JA; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Wilson, SR; Wiviott, SD; Zhou, S | 1 |
| Gillies, C; Manktelow, B; Potter, JF | 1 |
| Campos, H; Lee, SJ; Moye, LA; Sacks, FM | 1 |
| Forder, P; Hague, W; Hunt, D; Simes, J; Tonkin, A | 1 |
| Belder, R; de Grooth, GJ; Hu, B; Huang, SP; Jukema, JW; Kastelein, JJ; Kirchgessner, T; Klerkx, AH; Kuivenhoven, JA; Sacks, FM; Tsuchihashi, Z; Vishnupad, P; Zerba, KE; Zwinderman, AH | 1 |
| Amerena, J; Campbell, TJ; Harris, PJ; Meredith, I; Sloman, JG; Thompson, PL | 1 |
| Colquhoun, D; Gay, CA; Nestel, P; Pollicino, C; Simes, J; Stocker, R; Sullivan, D; Tonkin, A; Whiting, M | 1 |
| Armstrong, DF; Chan, P; Eagle, KA; Fang, J; Goldberg, AD; Kline-Rogers, E; Mukherjee, D; Nallamothu, BK; Patel, A; Rubenfire, M; Tsai, TT | 1 |
| Clearfield, M | 1 |
| Becker, C; Delmore, G; Hvalic, C; Krähenbühl, S; Schlienger, R | 1 |
| Choudhry, NK; Levin, R; Winkelmayer, WC | 1 |
| Kohriyama, T; Matsumoto, M; Nomura, E; Ohtsuki, T | 1 |
| Braunwald, E; Cannon, CP; Miller, M; Murphy, SA; Qin, J; Ray, KK | 1 |
| Hina, K; Iwasaki, K; Kita, T; Kusachi, S; Nishiyama, O; Takaishi, A; Taniguchi, G; Yamasaki, S | 1 |
| Hirota, Y; Ishii, K; Ishimura, T; Kawamura, K; Kita, Y; Onaka, H; Tsuji, R | 1 |
| Davis, BR; Meyers, DG; Rouleau, JL; Sacks, FM; Wilt, TJ | 1 |
| Daida, H; Lee, YJ; Miyano, H; Mokuno, H; Sakurai, H; Takaya, J; Yamaguchi, H; Yokoi, H | 1 |
| Arnold, JM; Braunwald, E; Brown, L; Cole, TG; Davis, BR; Moye, LA; Pfeffer, MA; Rouleau, JL; Rutherford, JD; Sacks, FM; Warnica, JW; Wun, CC | 1 |
| Pederson, JP; Weintraub, WS | 1 |
| Fuchi, T; Fujita, T; Hachisuka, M; Inoue, T; Kinoshita, M; Morigami, N; Nakamura, Y; Shimakawa, H; Sugimoto, Y; Uchida, K; Ueshima, H; Yamaoka, O | 1 |
| Willerson, JT | 1 |
| Force, R; Lawless, C | 1 |
| Hexeberg, E; Hjermann, I; Holme, I; Otterstad, JE | 1 |
| Donaldson, C; Glasziou, PP; Hall, J; Simes, RJ | 1 |
| Bassand, JP; Bertrand, ME; Cassagnes, J; Castaigne, A; Commeau, P; Danchin, N; Fruchart, JC; Grollier, G; Lablanche, JM; Machecourt, J; McFadden, EP; Mossard, JM; Vacheron, A; Van Belle, E | 1 |
| Braunwald, E; Cole, TG; Davis, BR; Moyé, LA; Nash, DT; Pfeffer, MA; Rouleau, JL; Sacks, FM | 1 |
| Braunwald, E; East, C; Glasser, S; Kell, S; Letterer, R; Lewis, SJ; Limacher, M; Mitchell, JS; Moye, LA; Pfeffer, MA; Rouleau, JL; Sacks, FM | 1 |
| Braunwald, E; Flaker, GC; Goldman, S; Moye, LA; Pfeffer, MA; Ridker, PM; Rifai, N; Sacks, FM | 1 |
| Ascher, NL; Ferrell, LD; Harihara, Y; Hashikura, Y; Inoue, Y; Kakizoe, S; Kawarasaki, H; Kawasaki, S; Kita, Y; Kiyosawa, K; Kubota, K; Lake, JR; Makuuchi, M; Mori, M; Ohtake, T; Ohtomo, K; Oka, T; Roberts, JP; Shiga, J; Takayama, T; Takikawa, H; Tanaka, E; Yotsuyanagi, H | 1 |
| Braunwald, E; Davis, BR; Glasser, SP; Grant, J; Johnstone, DE; Kell, S; Lewis, SJ; Limacher, M; Mitchell, J; Moye, LA; Pfeffer, MA; Sacks, FM; Timmis, G | 1 |
| Bombing, MT; Costa, A; Ferreira Filho, C; Ferreira, C; Luna Filho, B; Murad, N; Póvoa, R; Simões, M | 1 |
| Braunwald, E; East, C; Goldman, S; Moyé, LA; Nash, DT; Pfeffer, MA; Rouleau, JL; Rouleau, JR; Sacks, FM; Sussex, BA; Theroux, P; Vanden Belt, RJ | 1 |
| Beekman, M; Bruschke, AV; de Maat, MP; Henney, AM; Humphries, SE; Jukema, JW; Kastelein, JJ; Kluft, C; Moghaddam, PH; van Boven, AJ; Ye, S; Zwinderman, AH | 1 |
| Mahé, I | 1 |
| Arntz, HR | 1 |
| Babu, BR; Belew, K; Cohen, JD; Donohue, T; Drury, JH; Finn, J; Flaker, G; Labovitz, A; Ostdiek, J | 1 |
| Bertel, O; Darioli, R; Gutzwiller, F; Mordasini, R; Szucs, TD | 1 |
| Arnheim, K | 1 |
| Alaupovic, P; Braunwald, E; Cole, TG; Moye, LA; Pfeffer, MA; Sacks, FM; Stampfer, MJ; Sussex, B | 1 |
| Becker, SL; Marschner, IC | 1 |
| Alberts, MJ | 1 |
| Braunwald, E; Bray, PF; Cannon, CP; Goldschmidt-Clermont, P; Moyé, LA; Pfeffer, MA; Sacks, FM | 1 |
| Campos, H; Glasser, SP; Moye, LA; Sacks, FM; Stampfer, MJ | 1 |
| Braunwald, E; Brown, LE; Cole, TG; Hamm, P; Hawkins, CM; Moye', L; Pfeffer, MA; Sacks, FM | 1 |
4 review(s) available for pravastatin and Recrudescence
| Article | Year |
|---|---|
Interventions in the management of serum lipids for preventing stroke recurrence.
Topics: Cardiovascular Diseases; Clofibrate; Estrogens, Conjugated (USP); Humans; Hypolipidemic Agents; Pravastatin; Recurrence; Stroke | 2002 |
Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Coronary Disease; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Patient Compliance; Pravastatin; Recurrence; Risk Factors; Safety; Sex Factors; Treatment Outcome | 2003 |
[J-STARS (Japan statin treatment against recurrent stroke)].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Middle Aged; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Stroke | 2006 |
Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events.
Topics: Angina Pectoris; Anticholesteremic Agents; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Recurrence | 1999 |
41 trial(s) available for pravastatin and Recrudescence
| Article | Year |
|---|---|
Effect of Statin on Stroke Recurrence Prevention at Different Infarction Locations: A Post Hoc Analysis of The J-STARS Study.
Topics: Aged; Brain; Brain Infarction; Cerebrovascular Circulation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Ischemic Stroke; Male; Outcome Assessment, Health Care; Pravastatin; Proportional Hazards Models; Recurrence; Secondary Prevention | 2020 |
Pravastatin Reduces the Risk of Atherothrombotic Stroke when Administered within Six Months of an Initial Stroke Event.
Topics: Aged; Aged, 80 and over; Cohort Studies; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Japan; Male; Middle Aged; Pravastatin; Proportional Hazards Models; Recurrence; Risk; Stroke; Thrombosis; Time Factors | 2018 |
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
Topics: Adult; Aged; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Cholesterol; Cohort Studies; Combined Modality Therapy; Cytarabine; Cytogenetic Analysis; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pravastatin; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Cumulative Effects of LDL Cholesterol and CRP Levels on Recurrent Stroke and TIA.
Topics: Aged; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Ischemic Attack, Transient; Japan; Male; Pravastatin; Prognosis; Prospective Studies; Recurrence; Stroke | 2019 |
Baseline Carotid Intima-Media Thickness and Stroke Recurrence During Secondary Prevention With Pravastatin.
Topics: Aged; Brain Infarction; Carotid Intima-Media Thickness; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pravastatin; Recurrence; Stroke | 2019 |
Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study.
Topics: Adrenomedullin; Adult; Aged; Biomarkers; Coronary Disease; Female; Follow-Up Studies; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptide, Brain; Pravastatin; Predictive Value of Tests; Prognosis; Protein Precursors; Recurrence; Risk Assessment | 2014 |
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pravastatin; Recurrence; Time Factors; Treatment Outcome; Young Adult | 2014 |
Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction – ALPS-AMI study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydrophobic and Hydrophilic Interactions; Hypercholesterolemia; Japan; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Patient Acceptance of Health Care; Pravastatin; Recurrence; Single-Blind Method; Solubility | 2015 |
On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Leptin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Pyrroles; Recurrence; Resistin; Retrospective Studies; Risk Factors; Survival Rate; Thrombolytic Therapy; United States | 2015 |
The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study.
Topics: Aged; Asian People; Brain Ischemia; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Pravastatin; Proportional Hazards Models; Recurrence; Stroke | 2015 |
Risk stratification and treatment effect of statins in secondary cardiovascular prevention in old age: Additive value of N-terminal pro-B-type natriuretic peptide.
Topics: Age Factors; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Natriuretic Peptide, Brain; Netherlands; Peptide Fragments; Pravastatin; Prognosis; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention | 2016 |
The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Echo Study: Rationale and Trial Protocol.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Carotid Arteries; Carotid Intima-Media Thickness; Clinical Protocols; Female; Follow-Up Studies; Humans; Hyperlipidemias; Japan; Male; Middle Aged; Outcome Assessment, Health Care; Pravastatin; Recurrence; Statistics, Nonparametric; Stroke; Ultrasonography | 2017 |
Reduction in High-Sensitivity C-Reactive Protein Levels in Patients with Ischemic Stroke by Statin Treatment: Hs-CRP Sub-Study in J-STARS.
Topics: Aged; Aged, 80 and over; Brain Ischemia; C-Reactive Protein; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation; Male; Middle Aged; Pravastatin; Recurrence; Risk; Stroke | 2017 |
Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study.
Topics: Adiponectin; Aged; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Pravastatin; Recurrence; Risk; Stroke | 2009 |
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.
Topics: Aged; Biological Products; Cholesterol, LDL; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Life Style; Male; Middle Aged; Muscle Strength; Muscular Diseases; Pravastatin; Recurrence; Treatment Outcome | 2010 |
On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
Topics: Acute Coronary Syndrome; Atorvastatin; C-Reactive Protein; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Factors; Triglycerides | 2010 |
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
Topics: Acute Coronary Syndrome; Adiponectin; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Recurrence; Risk Assessment | 2011 |
Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Coronary Disease; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Patient Compliance; Pravastatin; Recurrence; Risk Factors; Safety; Sex Factors; Treatment Outcome | 2003 |
Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Cholesterol; Double-Blind Method; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Risk | 2004 |
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Triglycerides | 2008 |
[Preventive effect of pravastatin on restenosis following coronary angioplasty: prospective randomized trial].
Topics: Aged; Angioplasty, Balloon, Coronary; Cholesterol; Constriction, Pathologic; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prospective Studies; Recurrence | 1995 |
The effect of pravastatin on prevention of restenosis after successful percutaneous transluminal coronary angioplasty.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prospective Studies; Recurrence | 1994 |
Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240 mg/dL: baseline results from the Cholesterol and Recurrent Events (CARE) Study.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Coronary Disease; Cross-Sectional Studies; Female; Humans; Intracranial Arteriosclerosis; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peripheral Vascular Diseases; Pravastatin; Prevalence; Recurrence; Risk Factors; Smoking | 1996 |
Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Pravastatin; Probucol; Prospective Studies; Recurrence | 1996 |
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Survival Analysis; Treatment Outcome | 1996 |
Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study).
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Chi-Square Distribution; Cholesterol; Coronary Disease; Double-Blind Method; Female; Humans; Logistic Models; Male; Pravastatin; Prospective Studies; Recurrence | 1996 |
[Cholesterol lowering therapy after myocardial infarction. Consequences of the CARE study].
Topics: Adult; Aftercare; Aged; Anticholesteremic Agents; Cause of Death; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Norway; Pravastatin; Recurrence | 1997 |
Design of a cost-effectiveness study within a randomized trial: the LIPID Trial for Secondary Prevention of IHD. Long-term Intervention with Pravastatin in Ischemic Heart disease.
Topics: Absenteeism; Angina, Unstable; Anticholesteremic Agents; Australia; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Health Resources; Humans; Myocardial Infarction; New Zealand; Pravastatin; Quality-Adjusted Life Years; Recurrence; Research Design; Survival Analysis | 1997 |
Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Disease Progression; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prospective Studies; Recurrence; Treatment Outcome | 1997 |
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Female; Follow-Up Studies; Humans; Linear Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Recurrence; Risk Factors; Triglycerides | 1998 |
Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Artery Bypass; Double-Blind Method; Female; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Myocardial Infarction; Postmenopause; Pravastatin; Recurrence; Survival Rate | 1998 |
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.
Topics: Aged; Apolipoproteins; Arteriosclerosis; C-Reactive Protein; Cholesterol; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocarditis; Pravastatin; Protein Precursors; Recurrence; Risk Factors; Serum Amyloid A Protein | 1998 |
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Humans; Male; Myocardial Infarction; Pravastatin; Recurrence; Statistics as Topic | 1998 |
Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cohort Studies; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Survival Rate; Treatment Outcome; Triglycerides | 1999 |
Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events?
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Triglycerides; Vasodilation | 2000 |
[Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study].
Topics: Angina, Unstable; Anticholesteremic Agents; Cost-Benefit Analysis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Pravastatin; Recurrence | 2000 |
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial.
Topics: Apolipoprotein C-III; Apolipoproteins B; Apolipoproteins C; Apolipoproteins E; Body Constitution; Body Mass Index; Case-Control Studies; Cholesterol, VLDL; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Triglycerides | 2000 |
The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction.
Topics: Aged; Alleles; Anticholesteremic Agents; Female; Gene Deletion; Genotype; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptidyl-Dipeptidase A; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pravastatin; Protein Isoforms; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2001 |
Low-density lipoprotein size, pravastatin treatment, and coronary events.
Topics: Anticholesteremic Agents; Case-Control Studies; Cholesterol, LDL; Coronary Disease; Female; Humans; Logistic Models; Male; Middle Aged; Particle Size; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2001 |
Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE)
Topics: Adult; Aged; Algorithms; Cardiovascular Diseases; Cholesterol; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Research Design; Treatment Outcome | 1991 |
22 other study(ies) available for pravastatin and Recrudescence
| Article | Year |
|---|---|
Pravastatin for prevention of HELLP syndrome: A case report.
Topics: Adult; Female; Gestational Age; HELLP Syndrome; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Live Birth; Pravastatin; Pregnancy; Recurrence; Term Birth; Treatment Outcome | 2017 |
Ptosis, diplopia and statins: an association?
Topics: Adult; Atorvastatin; Autoantibodies; Autoimmune Diseases of the Nervous System; Azetidines; Blepharoptosis; Diabetes Complications; Diagnostic Errors; Diplopia; Eyelid Diseases; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Myasthenia Gravis; Myocardial Infarction; Pain; Pravastatin; Pyrroles; Receptors, Cholinergic; Recurrence; Strabismus | 2008 |
Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study.
Topics: Adult; Aged; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Middle Aged; Models, Statistical; Multivariate Analysis; Myocardial Infarction; Pravastatin; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2010 |
HMG CoA reduction in patients with average cholesterol concentrations.
Topics: Cholesterol; Coronary Artery Disease; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence | 2011 |
LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients.
Topics: Apolipoprotein C-III; Apolipoproteins C; Case-Control Studies; Cholesterol; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prospective Studies; Recurrence; Risk; Risk Factors; Triglycerides | 2003 |
The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB poly
Topics: Adult; Aged; Anticholesteremic Agents; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Female; Glycoproteins; Humans; Male; Middle Aged; Polymorphism, Genetic; Pravastatin; Prospective Studies; Recurrence; Site-Specific DNA-Methyltransferase (Adenine-Specific); Time Factors; Treatment Outcome | 2004 |
Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study.
Topics: Cardiovascular Diseases; Case-Control Studies; Coenzymes; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Placebos; Pravastatin; Prospective Studies; Recurrence; Regression Analysis; Risk; Ubiquinone | 2006 |
Effect of statin use in patients with acute coronary syndromes and a serum low-density lipoprotein
Topics: Acute Disease; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Coronary Disease; Follow-Up Studies; Humans; Michigan; Phenalenes; Pravastatin; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome | 2005 |
C-reactive protein levels and outcomes after statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2006 |
[Recurrent acute pancreatitis during pravastatin-therapy].
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pancreatitis; Pravastatin; Recurrence; Time Factors | 2006 |
Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
Topics: Aged; Atorvastatin; Chi-Square Distribution; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Treatment Outcome | 2007 |
Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Artery Disease; Death, Sudden, Cardiac; Humans; Lovastatin; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence; Scandinavian and Nordic Countries; Simvastatin; Survival Analysis | 1996 |
Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
Topics: Cholesterol; Controlled Clinical Trials as Topic; Humans; Myocardial Infarction; Pravastatin; Recurrence; Survival Rate | 1996 |
Lipid lowering in post-MI patients with normal cholesterol.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence; Reproducibility of Results; Sex Factors; Treatment Outcome | 1997 |
Possible recurrence of primary sclerosing cholangitis following living-related liver transplantation: report of a case.
Topics: Adult; Cholagogues and Choleretics; Cholangiography; Cholangitis, Sclerosing; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver Transplantation; Living Donors; Magnetic Resonance Imaging; Male; Mothers; Pravastatin; Recurrence; Ursodeoxycholic Acid | 1998 |
[Myocardial protection against cold stress with pravastatin].
Topics: Animals; Anticholesteremic Agents; Cholesterol; Cold Temperature; Heart; Male; Microscopy, Electron; Myocardial Infarction; Myocardium; Pravastatin; Rats; Rats, Wistar; Recurrence; Stress, Physiological | 1998 |
Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Artery Disease; Disease-Free Survival; Genotype; Humans; Male; Matrix Metalloproteinase 3; Multicenter Studies as Topic; Polymorphism, Genetic; Pravastatin; Promoter Regions, Genetic; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 1999 |
[What is the role of pravastatin in the secondary prevention of coronary disease?].
Topics: Adult; Aged; Angina, Unstable; Coronary Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence | 1999 |
[Coronary heart disease: grave deficiencies in secondary prevention. Almost no one is concerned with blood lipids].
Topics: Aged; Anticholesteremic Agents; Combined Modality Therapy; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Simvastatin; Survival Rate | 2000 |
Interim monitoring of clinical trials based on long-term binary endpoints.
Topics: Angina Pectoris; Anticholesteremic Agents; Cholesterol, HDL; Computer Simulation; Endpoint Determination; Humans; Numerical Analysis, Computer-Assisted; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Research Design | 2001 |
Suppression of recurrent transient ischemic attacks by a statin agent.
Topics: Aged; Anticholesteremic Agents; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pravastatin; Recurrence; Stroke | 2001 |
[Acute coronary syndrome. Early lipid reduction decreases risk of recurrence].
Topics: Angina, Unstable; Cholesterol, LDL; Humans; Hypercholesterolemia; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence | 2001 |